|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM311439462 |
| 003 |
DE-627 |
| 005 |
20231225142247.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108514
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1038.xml
|
| 035 |
|
|
|a (DE-627)NLM311439462
|
| 035 |
|
|
|a (NLM)32565324
|
| 035 |
|
|
|a (PII)S1521-6616(19)30604-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Tao, Juan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Circulating anti-C3b IgG in lupus nephritis
|b A large cohort study
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.02.2021
|
| 500 |
|
|
|a Date Revised 14.05.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The current study aimed to analyze the clinical significance and bio-functional properties of anti-C3b IgG based on a lupus nephritis cohort. We found that the prevalence of anti-C3b IgG in our cohort was 47.8%. Patients with positive anti-C3b IgG had significantly higher SLEDAI, lower circulating C3 and C4 levels. Anti-C3b IgG levels were positively correlated with C3 or C1q deposition in kidneys and several active pathological lesions. The positivity of anti-C3b IgG was an independent risk factor for the composite endpoints in the subgroup of proliferative lupus nephritis patients. In vitro, the purified IgG fractions from positive patients resulted in increased C3a generation through the alternative pathway, and interfered factor H and CR1 binding to C3b. Our findings indicated that anti-C3b IgG associated with local renal injury and long-term outcomes in lupus nephritis patients, possibly through leading to the complement alternative pathway over-activation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Anti-C3b IgG
|
| 650 |
|
4 |
|a Complement activation
|
| 650 |
|
4 |
|a Lupus nephritis
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a CFH protein, human
|2 NLM
|
| 650 |
|
7 |
|a CR1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Complement 3b
|2 NLM
|
| 650 |
|
7 |
|a Complement C3b
|2 NLM
|
| 650 |
|
7 |
|a 80295-43-8
|2 NLM
|
| 650 |
|
7 |
|a Complement Factor H
|2 NLM
|
| 650 |
|
7 |
|a 80295-65-4
|2 NLM
|
| 700 |
1 |
|
|a Song, Di
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Xiao-Ling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Feng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Ming-Hui
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 217(2020) vom: 10. Aug., Seite 108514
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:217
|g year:2020
|g day:10
|g month:08
|g pages:108514
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108514
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 217
|j 2020
|b 10
|c 08
|h 108514
|